id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10072 R36662 |
Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.65 [1.20;2.28] C excluded (control group) |
60/621 128/2,108 | 188 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7807 R23110 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.89 [1.45;2.47] C | 60/621 91,455/1,710,441 | 91,515 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5932 R15144 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
5.06 [0.91;28.06] C excluded (control group) |
2/13 6/173 | 8 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5913 R14935 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
4.74 [1.01;22.18] excluded (control group) |
2/13 21,546/719,509 | 21,548 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5921 R15031 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 4.57 [0.87;24.10] | 2/13 65/1,793 | 67 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.98 [1.36;2.88] | 91,582 | 634 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed, NOS; 2: Levetiracetam) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 5932, 5913, 10072